62. Paroxysmal nocturnal hemoglobinuria Clinical trials / Disease details

Clinical trials : 292 /  Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05731050
(ClinicalTrials.gov)		June 20251/2/2023Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)A Phase II, Open Label, Multi Dose Study of NM8074 in Soliris-Treated Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)PNH - Paroxysmal Nocturnal HemoglobinuriaDrug: NM8074NovelMed TherapeuticsNULLNot yet recruiting18 Years65 YearsAll6Phase 2NULL
2NCT05646524
(ClinicalTrials.gov)		November 202330/11/2022Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor TherapyA Phase II, Open-Label Study of NM8074 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal HemoglobinuriaDrug: NM8074NovelMed TherapeuticsNULLNot yet recruiting18 YearsN/AAll12Phase 2NULL
3NCT05646563
(ClinicalTrials.gov)		September 202330/11/2022Study of NM8074 in Adult PNH Patients With Inadequate Response to SolirisA Phase II, Open-Label Study of NM8074 in Soliris®-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal HemoglobinuriaDrug: NM8074;Drug: SolirisNovelMed TherapeuticsNULLNot yet recruiting18 YearsN/AAll12Phase 2NULL